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A key task for psychopharmacology is to establish which medicines can provide optimal 
clinical benefit with minimal levels of harm. Drugs that are considered to have no medical 
value and a high risk of misuse or harm are listed in Schedule 1 of the UK Misuse of Drugs 
Regulations 2001; these currently include cannabis, 3,4-methylenedioxymethamphetamine 
(MDMA) and psilocybin. Schedule 1 drugs cannot be possessed or prescribed by clinicians, 
and research is only permitted under a Home Office license that is costly and time intensive 
to obtain.   
 
By contrast, drugs that are deemed to have medical value despite a high liability for misuse or 
harm are placed in Schedule 2, including diamorphine, cocaine, amphetamines and ketamine. 
Research on these drugs is less restricted. They can be legally possessed by people with a 
prescription and possessed and supplied by pharmacists, doctors and dentists. Restrictions are 
lower still for drugs with widespread medical use listed in Schedules 3 to 5 such as 
buprenorphine and diazepam. In light of accumulating evidence supporting the medical value 
of Schedule 1 drugs including cannabis (Whiting et al., 2015), MDMA (Mithoefer et al., 
2018) and psilocybin (Ross et al., 2016), this legislation creates a barrier to research and the 
advancement of medical science. 
 
As part of a three-year commission from the Home Secretary, the Advisory Council for the 
Misuse of Drugs (ACMD) has been engaged in consultations on how research using Schedule 
1 drugs might be facilitated. Based on their initial consultations, several suggestions were 
raised by the research community. These included a blanket exemption from Schedule 1 for 
research (like the Psychoactive Substances Act 2016) or the provision of a single 
organisational licence to bring exemption from Schedule 1 requirements for academic 
institutions.  
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To capture the views of the British Association for Psychopharmacology (BAP) in these 
consultations, we conducted a survey in May 2018 on our members’ experiences of 
conducting research using controlled drugs.  We received 23 detailed responses from 
members with a range of backgrounds, including those in a clinical, preclinical and industrial 
setting. Only two of these 23 respondents had no suggestions for improvement. 
Overwhelmingly, our members consider that the current legislative framework requires 
improvement to facilitate research. Specifically, Home Office licenses were reported to be 
prohibitively costly (requiring both an initial and renewal fee, and highly specific and costly 
requirements for storage). Fu thermore, they were reported to create an unnecessary 
administrative burden and significant delays that could not be scientifically justified, given 
the low levels of risk compared to Schedule 2 drugs such as diamorphine (heroin).  
 
To give specific examples, in some cases the Home Office had requested ethical approval 
before granting an initial license; however, the relevant ethics committee had in turn 
requested Home Office approval before accepting an application - a classic Catch 22 situation 
- causing significant frustration, excess paperwork and long delays. From an industry 
perspective, our members reported that opportunities to work internationally had to be 
declined due to the excessive costs associated with the multiple import and export licenses 
required under the current framework. The limited duration of import and export licences 
raised further challenges. Our members suggested that research councils should be made 
aware of these issues, as it may be necessary to request additional resources and time to 
complete research studies. As one respondent put it: “As it stands, it is so difficult to even 
contemplate research in this area as you almost have to think ‘Right, we might, if all goes 
well, be able to start in 2 years.”  
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Several respondents pointed out that the current system is unnecessarily burdensome for 
researchers working with small quantities of Schedule 1 drugs. The Misuse of Drugs 
Regulations 2001 lists an exemption for small quantities. However, apart from lysergide or 
any other N-alkyl derivative of lysergamide (1 microgram) there is no drug-specific level of 
exemption, and 1 milligram applies to all drugs.  Problems were reported with obtaining a 
small quantity of a cannabinoid (total 10mg delta-9-tetrahydrocannabinol), leading to 
significant delay of a PhD student’s submission and their supervisor, an Associate Professor 
of psychiatry, deciding to abandon this line of research altogether: “In short, I can tell you 
without hesitation that the cu rent legislation surrounding controlled drugs is stifling 
research in this area: it has essentially dissuaded me from continuing my work. I no longer 
work on controlled drugs.” 
 
In contrast, experiences of working with Schedule 2 drugs were reported more favourably, 
providing a potential framework for legislation moving forwards: “We routinely use schedule 
II drugs for experiments in animals. Process for ordering and management work well. 
Schedule I drugs are much more difficult due to additional licensing which effectively 
precludes use using these compounds despite potential value for preclinical research.”  
 
Notably, the additional restrictions for Schedule 1 drugs was not considered scientific or 
appropriate given the level of risk: “The difference in regulations for using Schedule 2 drugs 
e.g. PCP and Schedule 1 drugs e.g. cannabinoids, and difficulty in using Schedule 1 drugs is 
not evidence based or scientific. The current UK drug laws are clearly hindering research at 
all levels.”  Although the ACMD initially considered that a blanket exemption of Schedule 1 
restrictions for the research community would not be workable, feedback from our survey 
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highlighted that a similar exemption already exists, as University research departments are 
not required to hold a Home Office license to possess and supply drugs in Schedules 2 to 5. It 
was argued that extending this exemption to Schedule 1 should not be problematic or lead to 
“unintended consequences”.  
 
Shortly after our survey was completed, a high-profile case emerged in which a 12-year old 
boy named Billy Caldwell and his mother travelled to Canada to obtain cannabis oil to 
control his epileptic seizures. When they returned to the UK on June 11
th
 2018, the cannabis 
oil was confiscated by the Home Office. The situation escalated when Billy was admitted to 
hospital with severe and potentially life-threatening seizures, resulting in an unprecedented 
decision from the Home Office to return the cannabis oil on June 16
th
. The Home Secretary, 
Sajid Javid, commissioned a two-stage review on medicinal uses of cannabis products, and a 
coalition of academics and clinicians led by several members of the BAP called on the 
government remove them from Schedule 1.  
 
The first stage of the review conducted by Chief Medical Officer Sally Davis stated: “There 
is now however, conclusive evidence of the therapeutic benefit of cannabis based medicinal 
products for certain medical conditions and reasonable evidence of therapeutic benefit in 
several other medical conditions…  As Schedule 1 drugs by definition have little or no 
therapeutic potential, it is therefore now clear that from a scientific point of view keeping 
cannabis based medicinal products in Schedule 1 is very difficult to defend.” The second 
stage of the review conducted by the ACMD agreed with this conclusion, recommending that 
cannabis-derived medicinal products (once clearly defined) should be moved from Schedule 
1 to Schedule 2.  
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Home Secretary announced on 26
th
 July 2018 that cannabis-derived medical products would 
be moved Schedule 2.  He should be commended for rapidly commissioning these two 
reviews, and for informing his decision using scientific evidence. This historical move broke 
the longstanding and illogical stalemate of holding drugs with medical value in Schedule 1. 
In their commissioned review, the ACMD also concluded that: “it is important that cannabis 
is not seen in isolation but as an example of a wider issue of potential ‘barriers to research’ 
associated with other drugs in Schedule 1.’” In light of the efficiency with which cannabis 
products were reviewed - and the clear conclusions reached - we now hope that scientific 
evidence and review can challenge the Schedule 1 status of other potential medicines, 
including MDMA and psilocybin.  
In conclusion, the results of our survey clearly demonstrate that current UK legislation 
hampers research into the consequences, and potential therapeutic benefits of Schedule 1 
drugs. We praise the government’s rapid response to cannabis based-medicinal products, and 
hope this will encourage further debate about the Misuse of Drugs Regulations and its impact 
on the field of psychopharmacology. 
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